CD105 expression in cancer-associated fibroblasts: a biomarker for bone metastasis in early invasive ductal breast cancer patients
Open Access
- 31 August 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1250869
Abstract
Introduction: Bone metastasis is one of the causes that mainly decrease survival in patients with advanced breast cancer. Therefore, it is essential to find prognostic markers for the occurrence of this type of metastasis during the early stage of the disease. Currently, cancer-associated fibroblasts, which represent 80% of the fibroblasts present in the tumor microenvironment, are an interesting target for studying new biomarkers and developing alternative therapies. This study evaluated the prognostic significance of the CD105 expression in cancer-associated fibroblasts in early breast cancer patients.Methods: Immunohistochemistry was used to assess CD105 expression in invasive ductal breast carcinomas (n = 342), analyzing its association with clinical and pathological characteristics.Results: High CD105 expression in cancer-associated fibroblasts was associated with an increased risk of metastatic occurrence (p = 0.0003), particularly bone metastasis (p = 0.0005). Furthermore, high CD105 expression was associated with shorter metastasis-free survival, bone metastasis-free survival, and overall survival (p = 0.0002, 0.0006, and 0.0002, respectively). CD105 expression also constituted an independent prognostic factor for metastasis-free survival, bone metastasis-free survival, and overall survival (p = 0.0003, 0.0006, and 0.0001, respectively).Discussion: The high CD105 expression in cancer-associated fibroblasts is an independent prognostic marker for bone metastasis in early breast cancer patients. Therefore, the evaluation of CD105(+) CAFs could be crucial to stratify BCPs based on their individual risk profile for the development of BM, enhancing treatment strategies and outcomes.Keywords
This publication has 53 references indexed in Scilit:
- Stromal biomarkers in breast cancer development and progressionClinical & Experimental Metastasis, 2012
- Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancersExperimental and Therapeutic Medicine, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Why the stroma matters in breast cancerCell Adhesion & Migration, 2012
- Influence of stromal–epithelial interactions on breast cancer in vitro and in vivoBreast Cancer Research and Treatment, 2011
- Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?Breast Cancer Research and Treatment, 2010
- Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patientsBreast Cancer Research and Treatment, 2010
- Fibroblasts in cancerNature Reviews Cancer, 2006
- ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancerAnnals of Oncology, 2005
- Breast Cancer Stromal Myxoid Changes Are Associated with Tumor Invasion and Metastasis: A Central Role for HyaluronanLaboratory Investigation, 2003